NASDAQ:VBLT Vascular Biogenics - VBLT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vascular Biogenics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.15 -0.03 (-17.17%) (As of 01/27/2023 08:56 PM ET) Add Compare Share Share Today's Range$0.15▼$0.2050-Day Range$0.11▼$0.1852-Week Range$0.10▼$2.20Volume6.87 million shsAverage Volume1.75 million shsMarket Capitalization$10.34 millionP/E RatioN/ADividend YieldN/APrice Target$5.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Vascular Biogenics MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside3,365.2% Upside$5.17 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector629th out of 1,049 stocksPharmaceutical Preparations Industry319th out of 514 stocks 3.1 Analyst's Opinion Consensus RatingVascular Biogenics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.17, Vascular Biogenics has a forecasted upside of 3,365.2% from its current price of $0.15.Amount of Analyst CoverageVascular Biogenics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.06% of the float of Vascular Biogenics has been sold short.Short Interest Ratio / Days to CoverVascular Biogenics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vascular Biogenics has recently decreased by 47.08%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVascular Biogenics does not currently pay a dividend.Dividend GrowthVascular Biogenics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VBLT. Previous Next 2.7 News and Social Media Coverage News SentimentVascular Biogenics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vascular Biogenics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for VBLT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Vascular Biogenics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vascular Biogenics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.13% of the stock of Vascular Biogenics is held by insiders.Percentage Held by InstitutionsOnly 4.81% of the stock of Vascular Biogenics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Vascular Biogenics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vascular Biogenics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVascular Biogenics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vascular Biogenics (NASDAQ:VBLT) StockVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.Read More Receive VBLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter. Email Address VBLT Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comVascular Biogenics (NASDAQ:VBLT) Coverage Initiated by Analysts at StockNews.comJanuary 22, 2023 | americanbankingnews.comVascular Biogenics (NASDAQ:VBLT) Coverage Initiated at StockNews.comJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 10, 2022 | finance.yahoo.comOYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue EstimatesSeptember 2, 2022 | finance.yahoo.comAxsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07September 1, 2022 | finance.yahoo.comVBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencySeptember 1, 2022 | finance.yahoo.comSorrento (SRNE) Gets FDA Fast Track Tag for Back Pain ProductAugust 2, 2022 | marketwatch.comVascular Biogenics Cutting About 35% of Staff >VBLTJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…August 2, 2022 | finance.yahoo.comVBL Therapeutics Announces Workforce ReductionJuly 21, 2022 | finance.yahoo.comVascular Biogenics (VBLT) Down, Ovarian Cancer Study FailsJuly 20, 2022 | msn.comGold Prices Settle Lower; Vascular Biogenics Shares PlummetJuly 20, 2022 | msn.comWhy Is Vascular Biogenics (VBLT) Stock Down 80% Today?July 20, 2022 | finance.yahoo.comRead Why VBL Therapeutics Shares Are Falling To a 52-Week LowJuly 19, 2022 | finance.yahoo.comVBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian CancerMay 31, 2022 | finance.yahoo.comVBL Therapeutics to Participate in the Jefferies Healthcare ConferenceMay 10, 2022 | finance.yahoo.comVBL Therapeutics to Report First Quarter 2022 Financial Results on May 17May 8, 2022 | finance.yahoo.comWhat Kind Of Shareholders Hold The Majority In Vascular Biogenics Ltd.'s (NASDAQ:VBLT) Shares?May 3, 2022 | finance.yahoo.comVBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in MayApril 26, 2022 | msn.comThe Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell ...April 16, 2022 | seekingalpha.comVascular Biogenics (VBLT) Presents at the KOL Event on Ovarian Cancer - SlideshowMarch 23, 2022 | finance.yahoo.comVBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate UpdateMarch 22, 2022 | benzinga.comVascular Biogenics Earnings PreviewMarch 22, 2022 | markets.businessinsider.comVascular Biogenics earnings: here's what Wall Street expectsMarch 14, 2022 | finance.yahoo.comUPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23March 8, 2022 | marketwatch.comVascular Biogenics Shares Rise Premarket on Phase 3 Ofra-Vec Study Update >VBLTMarch 8, 2022 | finance.yahoo.comVBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as PlannedSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VBLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter. Email Address VBLT Company Calendar Last Earnings11/14/2022Today1/30/2023Next Earnings (Estimated)3/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBLT Previous SymbolNASDAQ:VBLX CUSIPN/A CIK1603207 Webwww.vblrx.com Phone(728) 993-5000Fax972-8993-5001Employees41Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.17 High Stock Price Forecast$5.50 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+3,365.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,920,000.00 Net Margins-4,465.93% Pretax Margin-4,465.93% Return on Equity-99.67% Return on Assets-75.60% Debt Debt-to-Equity RatioN/A Current Ratio2.82 Quick Ratio2.82 Sales & Book Value Annual Sales$770,000.00 Price / Sales13.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book0.20Miscellaneous Outstanding Shares69,330,000Free Float65,077,000Market Cap$10.34 million OptionableOptionable Beta0.73 Key ExecutivesDror HaratsChief Executive Officer & DirectorEyal BreitbartSenior Vice President-Research & OperationsErez FeigeSenior Vice President-Business OperationsSamuel I. BackenrothChief Financial OfficerTami RachmilewitzSenior Vice President-Clinical DevelopmentKey CompetitorsCyclacel PharmaceuticalsNASDAQ:CYCCImunonNASDAQ:IMNNCingulateNASDAQ:CINGBellicum PharmaceuticalsNASDAQ:BLCMMinerva NeurosciencesNASDAQ:NERVView All CompetitorsInsiders & InstitutionsTelemetry Investments L.L.C.Bought 282,000 shares on 11/17/2022Ownership: 0.577%Two Sigma Investments LPBought 425,993 shares on 11/15/2022Ownership: 0.614%Renaissance Technologies LLCBought 332,600 shares on 11/14/2022Ownership: 0.480%Group One Trading L.P.Bought 112,148 shares on 11/9/2022Ownership: 0.423%Simplex Trading LLCBought 12,700 shares on 11/4/2022Ownership: 0.000%View All Institutional Transactions VBLT Stock - Frequently Asked Questions Should I buy or sell Vascular Biogenics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VBLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares. View VBLT analyst ratings or view top-rated stocks. What is Vascular Biogenics' stock price forecast for 2023? 4 Wall Street research analysts have issued 12 month price objectives for Vascular Biogenics' stock. Their VBLT share price forecasts range from $5.00 to $5.50. On average, they predict the company's share price to reach $5.17 in the next twelve months. This suggests a possible upside of 3,365.2% from the stock's current price. View analysts price targets for VBLT or view top-rated stocks among Wall Street analysts. How have VBLT shares performed in 2023? Vascular Biogenics' stock was trading at $0.12 at the beginning of the year. Since then, VBLT shares have increased by 24.3% and is now trading at $0.1491. View the best growth stocks for 2023 here. When is Vascular Biogenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our VBLT earnings forecast. How were Vascular Biogenics' earnings last quarter? Vascular Biogenics Ltd. (NASDAQ:VBLT) released its quarterly earnings data on Monday, November, 14th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.01. The biopharmaceutical company earned $0.48 million during the quarter, compared to analyst estimates of $0.15 million. Vascular Biogenics had a negative net margin of 4,465.93% and a negative trailing twelve-month return on equity of 99.67%. What other stocks do shareholders of Vascular Biogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN). What is Vascular Biogenics' stock symbol? Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT." How do I buy shares of Vascular Biogenics? Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vascular Biogenics' stock price today? One share of VBLT stock can currently be purchased for approximately $0.15. How much money does Vascular Biogenics make? Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $10.34 million and generates $770,000.00 in revenue each year. The biopharmaceutical company earns $-29,920,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. How can I contact Vascular Biogenics? Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001. This page (NASDAQ:VBLT) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.